PL4277628T3 - Taskwinimod lub jego farmaceutycznie dopuszczalna sól do stosowania w leczeniu zespołu mielodysplastycznego - Google Patents

Taskwinimod lub jego farmaceutycznie dopuszczalna sól do stosowania w leczeniu zespołu mielodysplastycznego

Info

Publication number
PL4277628T3
PL4277628T3 PL22700096.5T PL22700096T PL4277628T3 PL 4277628 T3 PL4277628 T3 PL 4277628T3 PL 22700096 T PL22700096 T PL 22700096T PL 4277628 T3 PL4277628 T3 PL 4277628T3
Authority
PL
Poland
Prior art keywords
tasquinimod
treatment
pharmaceutically acceptable
acceptable salt
myelodysplastic syndrome
Prior art date
Application number
PL22700096.5T
Other languages
English (en)
Inventor
Manja WOBUS
Katja SOCKEL
Martin BORNHÄUSER
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of PL4277628T3 publication Critical patent/PL4277628T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL22700096.5T 2021-01-18 2022-01-17 Taskwinimod lub jego farmaceutycznie dopuszczalna sól do stosowania w leczeniu zespołu mielodysplastycznego PL4277628T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21152018 2021-01-18
EP21201509 2021-10-07
EP21205665 2021-10-29
PCT/EP2022/050891 WO2022152902A1 (en) 2021-01-18 2022-01-17 Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome

Publications (1)

Publication Number Publication Date
PL4277628T3 true PL4277628T3 (pl) 2026-02-09

Family

ID=80034981

Family Applications (1)

Application Number Title Priority Date Filing Date
PL22700096.5T PL4277628T3 (pl) 2021-01-18 2022-01-17 Taskwinimod lub jego farmaceutycznie dopuszczalna sól do stosowania w leczeniu zespołu mielodysplastycznego

Country Status (11)

Country Link
US (1) US20240091215A1 (pl)
EP (1) EP4277628B1 (pl)
JP (1) JP2024503372A (pl)
KR (1) KR20230133317A (pl)
AU (1) AU2022208424A1 (pl)
CA (1) CA3204120A1 (pl)
IL (1) IL304232A (pl)
MX (1) MX2023008016A (pl)
PL (1) PL4277628T3 (pl)
WO (1) WO2022152902A1 (pl)
ZA (1) ZA202307855B (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4346773T3 (pl) 2021-05-25 2025-11-03 Active Biotech Ab Duża liczba cząstek taskwinimodu i ich zastosowanie
WO2024137713A1 (en) * 2022-12-20 2024-06-27 Constellation Pharmaceuticals, Inc. Methods for treating lower risk myelodysplastic syndrome

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
EA021171B1 (ru) 2010-07-09 2015-04-30 Эктив Байотек Аб Способ получения хинолин-3-карбоксамидов
EP2537517A1 (en) 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
EP3711484A1 (en) * 2013-07-05 2020-09-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Soluble cd33 for treating myelodysplastic syndromes (mds)
EP3110409B1 (en) * 2014-02-28 2018-08-15 Incyte Corporation Jak1 inhibitors for the treatment of myelodysplastic syndromes
CN107108510B (zh) 2014-09-23 2020-10-23 活跃生物技术有限公司 用于治疗多发性骨髓瘤的喹啉甲酰胺
EP3180005B1 (en) 2014-11-19 2017-12-27 Active Biotech AB Quinoline carboxamides for use in the treatment of leukemia
EP3067062A1 (en) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
BR112020006845A2 (pt) * 2017-10-06 2020-10-06 Tesaro, Inc. terapias combinadas e usos das mesmas
JP2019127473A (ja) * 2018-01-26 2019-08-01 学校法人同志社 多発性硬化症の治療及び／又は予防のための薬剤

Also Published As

Publication number Publication date
US20240091215A1 (en) 2024-03-21
CA3204120A1 (en) 2022-07-21
IL304232A (en) 2023-09-01
WO2022152902A1 (en) 2022-07-21
AU2022208424A1 (en) 2023-08-24
MX2023008016A (es) 2023-07-13
AU2022208424A9 (en) 2024-05-09
EP4277628B1 (en) 2025-09-24
KR20230133317A (ko) 2023-09-19
JP2024503372A (ja) 2024-01-25
EP4277628C0 (en) 2025-09-24
EP4277628A1 (en) 2023-11-22
ZA202307855B (en) 2025-12-17

Similar Documents

Publication Publication Date Title
IL282727B1 (en) Combination therapy comprising a Krasg12c inhibitor and one or more pharmacologically active agents for the treatment of cancers
GB2590793B (en) Cannabidiol-C1 for use as a medicament and in the treatment of epilepsy
PL3577135T3 (pl) Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5
IL190284A (en) Use of milenzipran, or a suitable pharmaceutical salt, in the preparation of a drug for the treatment of fibromyalgia
IL314347A (en) Combined treatment of lasmiditan and a CGRP antagonist for use in the treatment of migraine
PL3829628T3 (pl) Kompozycja farmaceutyczna do zastosowania w leczeniu lub zapobieganiu chorobie związanej z C5
SG11202011261PA (en) Urolithin a and derivatives thereof for use in therapy
GB202103211D0 (en) Pharmaceutical compounds for use in therapy
PL4277628T3 (pl) Taskwinimod lub jego farmaceutycznie dopuszczalna sól do stosowania w leczeniu zespołu mielodysplastycznego
GB2587172B (en) Pyronaridine or pharmaceutically acceptable salts thereof for the treatment of cancer
MX2019015212A (es) Compuestos para el tratamiento del sarcoma.
IL236041A (en) 1- [6 - [[5- (2-Fluoropropyl) -3-methyl-triazole-4-yl] methoxy] -3-pyridyl] imidazole-4-carbonitrile or its common pharmaceutical salt and such compound for use in the treatment of diseases
GB202019475D0 (en) Therapeutic compounds and their use
GB202108572D0 (en) Therapeutic compounds and their use
MX2019015280A (es) Composiciones de estatinas y metodos para su uso en el tratamiento de sinucleinopatias.
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
LT3697399T (lt) Terapiniai agentai, skirti panaudoti gydant neramių kojų sindromą
ZA202101652B (en) Novel thiazole derivatives and pharmaceutically acceptable salts thereof
HK40100349A (en) Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
PL4072532T3 (pl) Postać dawkowania do zastosowania w leczeniu lub zapobieganiu chorobie
IL272562B1 (en) Compounds or pharmaceutically acceptable salts thereof for the treatment of mycobacterial infection
PL3937949T3 (pl) Fitoekdyzony i ich pochodne do ich zastosowania w leczeniu upośledzenia funkcji oddechowych
IL304737A (en) Dangapetide for the treatment or prevention of kidney disease
PL4114368T3 (pl) Taskwinimod lub jego farmaceutycznie dopuszczalna sól do stosowania w terapii skojarzonej
IL286029A (en) Potassium binding agents for use in hemodialysis patients